Perrigo Company plc
- Open
- 14.71
- Day high
- 14.80
- Day low
- 14.25
- Prev close
- 14.49
- Volume
- 80K
- Mkt cap
- $2.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.8
- P/S
- 0.5
- Yield
- 8.12%
- Per share
- $1.16
Perrigo Company plc (PRGO) is a Healthcare company listed on NYSE. The stock is down 37% over the past year. Drillr has 1 published research article covering PRGO.
Perrigo Company plc (PRGO) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PRGO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $0.39 | $0.50 | +28.9% | $1.0B | +0.7% |
| May 6, 2026 | $0.39 | $0.43 | +10.3% | $969M | -6.4% |
| Feb 26, 2026 | $0.80 | $0.77 | -3.8% | $1.1B | +1.6% |
| Nov 5, 2025 | $0.75 | $0.80 | +6.7% | $1.0B | -4.5% |
| Aug 6, 2025 | $0.59 | $0.57 | -3.4% | $1.1B | -4.0% |
| Feb 27, 2025 | $0.92 | $0.93 | +1.1% | $1.1B | +4.4% |
| Aug 2, 2024 | $0.48 | $0.53 | +10.4% | $1.1B | -5.7% |
| Feb 27, 2024 | $0.83 | $0.86 | +3.6% | $1.2B | -1.6% |
| Feb 27, 2023 | $0.70 | $0.75 | +7.1% | $1.2B | -1.1% |
| Mar 1, 2022 | $0.56 | $0.60 | +7.1% | $1.1B | +0.5% |
| Nov 10, 2021 | $0.65 | $0.45 | -30.8% | $1.0B | -23.5% |
| Aug 11, 2021 | $0.61 | $0.50 | -18.0% | $981M | -3.6% |
PRGO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 23, 2026 | Manzone Albertdirector, officer: Interim President and CEO | Grant | 235,627 | — |
| Jul 15, 2026 | Gajial Muhammad Omerdirector | Grant | 14,964 | — |
| Jul 15, 2026 | Amin Ahmed Salmandirector | Grant | 14,964 | — |
| Jul 10, 2026 | Lennox Abigailofficer: EVP and CSO | Grant | 84,826 | — |
| Jul 10, 2026 | Willis Robertofficer: EVP & CHRO | Grant | 60,085 | — |
| Jul 10, 2026 | Khoury Robertoofficer: EVP and President of CSCI | Grant | 113,101 | — |
| Jul 10, 2026 | Atkinson Charlesofficer: EVP, General Counsel & Sec. | Grant | 123,704 | — |
| Jul 10, 2026 | Winterman Matthew Johnofficer: EVP, Supply, Ops, Strategy | Grant | 70,688 | — |
| Jul 10, 2026 | Ball Davidofficer: EVP & CBDO | Grant | 70,688 | — |
| Jul 10, 2026 | Bezerra Eduardo Guaritaofficer: EVP & Chief Financial Officer | Grant | 141,376 | — |
| Jul 9, 2026 | Khoury Robertoofficer: EVP and President of CSCI | Option | 737 | $10.52 |
| Jul 9, 2026 | Winterman Matthew Johnofficer: EVP, Supply, Ops, Strategy | Tax | 963 | $10.52 |
| Jul 9, 2026 | Winterman Matthew Johnofficer: EVP, Supply, Ops, Strategy | Option | 1,843 | $10.52 |
| Jul 9, 2026 | Khoury Robertoofficer: EVP and President of CSCI | Tax | 385 | $10.52 |
| Jul 9, 2026 | Winterman Matthew Johnofficer: EVP, Supply, Ops, Strategy | Tax | 8,175 | $10.52 |
Source: PRGO SEC Form 4 filings, latest Jul 23, 2026. For informational purposes only — not investment advice.
See the full PRGO insider & 13F page →Perrigo Company plc company profile
Overview
Perrigo Company plc (NYSE:PRGO) is a Dublin-based consumer healthcare company founded in 1887 that has evolved from a small Michigan pharmacy into a global leader in over-the-counter health and wellness products. The company operates as one of the world's largest manufacturers of store-brand consumer healthcare products, serving both retail chains and consumers directly through its own branded products. Perrigo has undergone significant transformation in recent years, divesting its prescription pharmaceuticals business to focus exclusively on consumer self-care products across the Americas and international markets.
Business
Perrigo operates in the consumer healthcare industry, specifically focusing on over-the-counter (OTC) medications and wellness products that consumers can purchase without a prescription. The company's core business revolves around developing, manufacturing, and distributing products that help people manage common health conditions independently, from cold and flu symptoms to pain relief, digestive issues, and personal care needs. The company operates through two primary business segments: **Consumer Self-Care Americas (CSCA)** represents the larger portion of Perrigo's business, focusing primarily on store-brand products sold in the United States, Mexico, Canada, and South America. This segment manufactures private-label versions of popular OTC medications and wellness products for major retailers like Walmart, CVS, and Walgreens. Key product categories include upper respiratory treatments (cough and cold medications), pain relievers and sleep aids, digestive health products, vitamins and nutritional supplements, skincare and personal hygiene items, and oral care products. The segment also includes infant formula manufacturing, which has been a significant focus area due to recent production challenges and market opportunities. **Consumer Self-Care International (CSCI)** operates primarily in Europe across approximately 23 countries, developing and marketing both store-brand and proprietary branded products. This segment distributes through pharmacies, wholesalers, drug stores, grocery retailers, and para-pharmacies. Notable brands in this segment include Compeed (blister treatment), ellaOne (emergency contraception), and Paranix (lice treatment). The international segment has been bolstered by the 2021 acquisition of HRA Pharma, which strengthened Perrigo's women's health portfolio and European market presence. The company also offers contract manufacturing services to other healthcare companies, leveraging its production capabilities and regulatory expertise. Additionally, Perrigo has been expanding into OTC branded products in the U.S. market, including the launch of Opill, the first over-the-counter daily oral contraceptive approved in the United States.
Revenue model
Perrigo generates revenue primarily through product sales to retailers and distributors, operating on a business-to-business model where major retail chains are the primary customers. The company's revenue streams include manufacturing and selling store-brand products to retailers who then sell them under their private labels, selling proprietary branded products directly to retailers and distributors, and providing contract manufacturing services to other pharmaceutical and consumer health companies. The company's customers are predominantly large retail chains, pharmacy chains, wholesalers, and distributors rather than end consumers. In the Americas, major customers include Walmart, CVS Health, Walgreens, and other national and regional retailers. Internationally, the customer base consists of pharmacy chains, wholesalers, and para-pharmacy retailers across Europe and other international markets. Several factors significantly impact Perrigo's margins and profitability. Commodity and raw material costs directly affect manufacturing expenses, with recent inflationary pressures requiring pricing adjustments and supply chain optimization. Regulatory compliance costs are substantial, particularly for infant formula production, which requires extensive quality assurance and FDA oversight. Seasonal demand patterns create variability, with cough and cold products seeing higher demand during winter months. Competition from national brands and other private-label manufacturers can pressure pricing, though economic downturns often benefit store-brand products as consumers seek value alternatives. Tariff impacts have become increasingly significant, with the company expecting approximately 5.5% increases in global cost of goods sold due to trade policy changes. The company's ability to pass through cost increases to retailers and implement operational efficiencies through programs like Project Energize directly impacts margin sustainability. Market share dynamics in key categories like infant formula can create substantial revenue swings, as demonstrated by the recent production challenges and recovery efforts.
Competitive moat
Perrigo's competitive moat is moderately strong but faces ongoing challenges from multiple directions. The company's primary competitive advantages stem from its manufacturing scale and regulatory expertise, particularly in navigating the complex FDA approval processes for OTC medications and infant formula production. This regulatory knowledge creates barriers for new entrants and provides switching costs for retail customers who rely on Perrigo's compliance capabilities. The company benefits from established relationships with major retailers who depend on Perrigo's ability to deliver consistent, high-quality store-brand alternatives to national brand products. These relationships are reinforced by Perrigo's broad product portfolio, which allows retailers to source multiple categories from a single supplier, reducing complexity and procurement costs. However, Perrigo's moat faces several vulnerabilities. The private-label manufacturing business is inherently commoditized, with limited pricing power and constant pressure to reduce costs. Retailers can and do switch suppliers based on price and service levels, as evidenced by recent lost distribution mentioned in earnings calls. National brand manufacturers can compete directly by offering their own private-label manufacturing services or by aggressive pricing of their branded products. The infant formula segment demonstrates both the potential strength and fragility of Perrigo's position. While the segment offers higher margins and the company has significant manufacturing capabilities, recent production quality issues have shown how quickly market share can be lost and how difficult it can be to recover. Competition from established players like Abbott and Reckitt Benckiser, as well as potential new entrants, creates ongoing pressure. Perrigo's expansion into proprietary branded products like Opill represents an attempt to build a stronger moat through brand recognition and direct consumer relationships, but this strategy is still in early stages and faces competition from well-established pharmaceutical companies with deeper marketing resources.
Risks & safety
**Overall Assessment**: Perrigo demonstrates reasonable financial stability with adequate liquidity, though profitability challenges and debt levels require monitoring. **Cash and Liquidity**: - Cash position of $410 million (Q1 2025) provides reasonable short-term flexibility - Current ratio of 2.36 indicates strong ability to meet short-term obligations - Quick ratio of 1.28 shows adequate liquid assets relative to current liabilities **Debt and Solvency**: - Debt-to-equity ratio of 0.83 represents moderate leverage levels - Total liabilities of $5.4 billion against $9.8 billion in assets - Operating cash flow variability (-$65M in Q1 2025 vs. +$313M in Q4 2024) raises concerns about cash generation consistency **Profitability and Valuation**: - Recent quarterly losses with negative ROE of -0.15% indicate profitability challenges - EV/EBITDA of 13.9x appears reasonable for the sector - Price-to-book ratio of 0.89 suggests potential undervaluation - Free cash flow turning negative (-$90M in Q1 2025) requires attention **Other Considerations**: - Ongoing infant formula production issues create operational risks - Tariff impacts expected to increase costs by 5.5% globally - Project Energize cost-saving initiatives may help offset margin pressures
Recent development
Over the past few years, Perrigo has undergone significant strategic transformation focused on streamlining operations and positioning for sustainable growth. The company implemented Project Energize, a comprehensive cost-reduction initiative targeting $140-170 million in annual pre-tax savings by 2026, which has already delivered $159 million in cumulative benefits. This program included workforce reductions and operational efficiency improvements across the organization. The company has been executing a "Three-S" strategic framework consisting of Stabilize, Streamline, and Strengthen initiatives. Stabilization efforts have focused on improving service levels, which reached 94% in recent quarters, and securing new business awards in store-brand OTC products. Streamlining activities include supply chain reinvention programs that have generated $8 million in quarterly benefits and the implementation of a "One Perrigo" operating platform to unify technology systems and organizational structure. Infant formula recovery has been a major focus following production quality issues that significantly impacted the business. The company has invested heavily in manufacturing upgrades, quality assurance improvements, and is preparing to launch 60 new infant formula SKUs to recapture market share. Production volumes have recovered to near-normal levels, with in-stock rates improving to approximately 85% across major customers. The launch of Opill, the first over-the-counter daily oral contraceptive in the United States, represents Perrigo's strategic pivot toward proprietary branded products. The product has gained nearly 3% market share and demonstrates the company's capability to bring innovative products to market through its regulatory expertise. Perrigo has also been exploring opportunities in emerging health trends, including potential products related to GLP-1 medication side effects and expanding its women's health portfolio. The company paused major capital investments in its nutrition network to focus resources on higher-priority initiatives while maintaining flexibility for future growth opportunities.
PRGO company profile · for informational purposes only — not investment advice.
Track PRGO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free